Combining Neuroendocrine Inhibitors in Heart Failure: Reflections on Safety and Efficacy

Hani Jneid, George V. Moukarbel, Bart Dawson, Roger J. Hajjar, Gary S. Francis

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations

Abstract

Neuroendocrine activation in heart failure has become the major target of pharmacotherapy for this growing epidemic. Agents targeting the renin-angiotensin-aldosterone and sympathetic nervous systems have shown cardiovascular and survival benefits in clinical trials. Beta-blockers and angiotensin-converting enzyme (ACE) inhibitors remain the mainstream initial therapy. The benefits of aldosterone antagonists have been demonstrated in advanced heart failure (spironolactone) and after myocardial infarction complicated by left ventricular dysfunction and heart failure (eplerenone). Emerging clinical evidence demonstrated that angiotensin receptor blockers may be a reasonable alternative to ACE inhibitors in patients with heart failure (candesartan) and following myocardial infarction complicated by heart failure or left ventricular dysfunction (valsartan). Angiotensin receptor blockers (candesartan) also provided incremental benefits when added to ACE inhibitors in chronic heart failure. Thus, combining neuroendocrine inhibitors in heart failure appears both biologically plausible and evidence-based. However, this approach raised concerns about side effects, such as hypotension, renal insufficiency, hyperkalemia, and others. Close follow-up and implementation of evidence-based medicine (ie, using agents and doses proven beneficial in clinical trials) should therefore be undertaken when combining neuroendocrine inhibitors.

Original languageEnglish (US)
JournalAmerican Journal of Medicine
Volume120
Issue number12
DOIs
StatePublished - Dec 1 2007

Keywords

  • Aldosterone
  • Angiotensin
  • Beta-blocker
  • Heart failure
  • Neuroendocrine
  • Systolic dysfunction

Fingerprint Dive into the research topics of 'Combining Neuroendocrine Inhibitors in Heart Failure: Reflections on Safety and Efficacy'. Together they form a unique fingerprint.

Cite this